select a format

Single User License
USD 2000 INR 130040
Site License
USD 4000 INR 260080
Corporate User License
USD 6000 INR 390120


Request a quote
Request a Customized research
Request for Sample Report


Recent Viewed Reports

Why Ken Reasearch?


The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements.... "Senior Associate, Booz Allen Hamilton"

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

Dengue-Pipeline Review, H1 2015

Dengue-Pipeline Review, H1 2015

  • Products Id :- GMDHC6019IDB
  • |
  • Pages: 187
  • |
  • January 2015
  • |
  • |
  Request for Sample Report

Executive Summary

Dengue-Pipeline Review, H1 2015


Global Markets Direct's, 'Dengue-Pipeline Review, H1 2015', provides an overview of the Dengue's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Dengue, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Dengue and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides a snapshot of the global therapeutic landscape of Dengue

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Dengue and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Dengue products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Dengue pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Dengue

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Dengue pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
ankur [@]

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Dengue Overview 9

Therapeutics Development 10

Pipeline Products for Dengue-Overview 10

Pipeline Products for Dengue-Comparative Analysis 11

Dengue-Therapeutics under Development by Companies 12

Dengue-Therapeutics under Investigation by Universities/Institutes 16

Dengue-Pipeline Products Glance 18

Late Stage Products 18

Clinical Stage Products 19

Early Stage Products 20

Unknown Stage Products 21

Dengue-Products under Development by Companies 22

Dengue-Products under Investigation by Universities/Institutes 26

Dengue-Companies Involved in Therapeutics Development 28

Agilvax, Inc. 28

AltraVax Inc. 29

Arbovax, Inc. 30

BioDiem Ltd 31

Biotron Limited 32

Cocrystal Pharma, Inc. 33

Codagenix, Inc. 34

FIT Biotech Oyj 35

GlaxoSmithKline plc 36

Humabs BioMed SA 37

Immunovaccine, Inc. 38

Johnson & Johnson 39

Kineta, Inc. 40

MacroGenics, Inc. 41

Medivir AB 42

Merck & Co., Inc. 43

Molplex Ltd. 44

Myelo Therapeutics GmbH 45

NanoViricides, Inc. 46

Panacea Biotec Limited 47

PaxVax 48

Prosetta Antiviral Inc. 49

RFS Pharma, LLC 50

Sanofi Pasteur SA 51

Sarepta Therapeutics, Inc. 52

SIGA Technologies, Inc. 53

SKAU Vaccines ApS 54

Takeda Pharmaceutical Company Limited 55

TechnoVax, Inc. 56

Themis Bioscience GmbH 57

United Therapeutics Corporation 58

VaxInnate Corporation 59

Visterra, Inc. 60

Dengue-Therapeutics Assessment 61

Assessment by Monotherapy Products 61

Assessment by Target 62

Assessment by Mechanism of Action 64

Assessment by Route of Administration 66

Assessment by Molecule Type 68

Drug Profiles 70

BG-323-Drug Profile 70

celgosivir hydrochloride-Drug Profile 71

dengue (tetravalent) vaccine-Drug Profile 72

dengue (tetravalent) vaccine-Drug Profile 73

dengue (tetravalent) vaccine 4-Drug Profile 74

dengue [DENV-2] vaccine-Drug Profile 75

dengue [rDEN1delta30, rDEN2/4delta30(ME), rDEN3delta30/31 and rDEN4delta30] (tetravalent) vaccine-Drug Profile 76

dengue [serotypes 1,2,3,4] (tetravalent) vaccine-Drug Profile 77

dengue fever vaccine-Drug Profile 80

dengue vaccine-Drug Profile 81

dengue vaccine-Drug Profile 82

dengue vaccine-Drug Profile 83

dengue vaccine-Drug Profile 85

dengue vaccine-Drug Profile 86

dengue vaccine-Drug Profile 87

dengue vaccine-Drug Profile 88

dengue vaccine-Drug Profile 89

dengue vaccine (DENV-2)-Drug Profile 90

dengue vaccine (tetravalent)-Drug Profile 91

dengue vaccine (tetravalent)-Drug Profile 93

dengue vaccine (tetravalent)-Drug Profile 94

dengue vaccine [DEN-1 and DEN-2]-Drug Profile 95

dengue vaccine [DEN-2]-Drug Profile 96

dengue vaccine 3-Drug Profile 97

dengue vaccine 4-Drug Profile 99

dengue vaccines-Drug Profile 100

dengue virus vaccine-Drug Profile 101

dengue virus vaccine (tetravalent)-Drug Profile 102

DengueCide-Drug Profile 103

DENV-1 PIV-Drug Profile 104

DiTU-Drug Profile 105

DV-2-DeltaGVII-Drug Profile 106

DV-2-DeltaLIG-Drug Profile 107

DV-2-G460P-Drug Profile 108

ETX-101-Drug Profile 110

GBV-001-Drug Profile 111

GBV-006-Drug Profile 112

GBV-012-Drug Profile 113

GREDEN/V1-4-Drug Profile 114

LCTA-949-Drug Profile 115

LVM-142-Drug Profile 116

modipafant-Drug Profile 117

Monoclonal Antibodies for Infectious Disease-Drug Profile 118

Monoclonal Antibodies to Inhibit prM and E Proteins for Dengue-Drug Profile 119

Monoclonal Antibody for Dengue-Drug Profile 120

Monoclonal Antibody for Dengue-Drug Profile 121

Myelo-001-Drug Profile 122

PAV-866-Drug Profile 123

Recombinant Peptide to Inhibit Dengue Protease for Dengue-Drug Profile 124

RNAi Oligonucleotide for Dengue-Drug Profile 125

rOAS-Drug Profile 126

RS-1137-Drug Profile 127

RS-1142-Drug Profile 128

RS-1145-Drug Profile 129

RS-930-Drug Profile 130

RS-961-Drug Profile 131

Small Molecule for Dengue-Drug Profile 132

Small Molecule for Dengue-Drug Profile 133

Small Molecule Inhibitors of NS3 Protease for Dengue and West Nile Virus Infections-Drug Profile 134

Small Molecule to Inhibit NS3 Protease for Dengue-Drug Profile 135

Small Molecules for Dengue-Drug Profile 136

Small Molecules for Dengue-Drug Profile 137

Small Molecules Inhibiting M Protein for Dengue-Drug Profile 138

Small Molecules to Activate AMPK for Dengue-Drug Profile 139

Small Molecules to Inhibit Alpha-Glucosidase I and II for Viral Infections-Drug Profile 140

Small Molecules to Inhibit Furin for Dengue-Drug Profile 142

Small Molecules to Inhibit NS3 Protease for Dengue and West Nile Virus Infections-Drug Profile 143

Small Molecules to Inhibit NS4b for Dengue-Drug Profile 144

Small Molecules to Inhibit Protease for Dengue-Drug Profile 145

Small Molecules to Inhibit RNA Dependent RNA Polymerase for Dengue Virus Infections-Drug Profile 146

Small Molecules to Inhibit Serine Protease for Viral Infections-Drug Profile 147

ST-148-Drug Profile 148

ST-324-Drug Profile 149

ST-610-Drug Profile 150

Synthetic Peptides for West Nile Virus and Dengue Virus Infections-Drug Profile 151

TAK-003-Drug Profile 152

TVX-005-Drug Profile 154

UV-4B-Drug Profile 155

V-180-Drug Profile 156

Viral PMO-X-Drug Profile 157

VIS-513-Drug Profile 158

Dengue-Recent Pipeline Updates 159

Dengue-Dormant Projects 165

Dengue-Discontinued Products 167

Dengue-Product Development Milestones 168

Featured News & Press Releases 168

Appendix 180

Methodology 180

Coverage 180

Secondary Research 180

Primary Research 180

Expert Panel Validation 180

Contact Us 181

Disclaimer 181

List of Tables

Number of Products under Development for Dengue, H1 2015 16

Number of Products under Development for Dengue-Comparative Analysis, H1 2015 17

Number of Products under Development by Companies, H1 2015 19

Number of Products under Development by Companies, H1 2015 (Contd..1) 20

Number of Products under Development by Companies, H1 2015 (Contd..2) 21

Number of Products under Investigation by Universities/Institutes, H1 2015 23

Comparative Analysis by Late Stage Development, H1 2015 24

Comparative Analysis by Clinical Stage Development, H1 2015 25

Comparative Analysis by Early Stage Development, H1 2015 26

Comparative Analysis by Unknown Stage Development, H1 2015 27

Products under Development by Companies, H1 2015 28

Products under Development by Companies, H1 2015 (Contd..1) 29

Products under Development by Companies, H1 2015 (Contd..2) 30

Products under Development by Companies, H1 2015 (Contd..3) 31

Products under Investigation by Universities/Institutes, H1 2015 32

Products under Investigation by Universities/Institutes, H1 2015 (Contd..1) 33

Dengue-Pipeline by Agilvax, Inc., H1 2015 34

Dengue-Pipeline by AltraVax Inc., H1 2015 35

Dengue-Pipeline by Arbovax, Inc., H1 2015 36

Dengue-Pipeline by BioDiem Ltd, H1 2015 37

Dengue-Pipeline by Biotron Limited, H1 2015 38

Dengue-Pipeline by Cocrystal Pharma, Inc., H1 2015 39

Dengue-Pipeline by Codagenix, Inc., H1 2015 40

Dengue-Pipeline by FIT Biotech Oyj, H1 2015 41

Dengue-Pipeline by GlaxoSmithKline plc, H1 2015 42

Dengue-Pipeline by Humabs BioMed SA, H1 2015 43

Dengue-Pipeline by Immunovaccine, Inc., H1 2015 44

Dengue-Pipeline by Johnson & Johnson, H1 2015 45

Dengue-Pipeline by Kineta, Inc., H1 2015 46

Dengue-Pipeline by MacroGenics, Inc., H1 2015 47

Dengue-Pipeline by Medivir AB, H1 2015 48

Dengue-Pipeline by Merck & Co., Inc., H1 2015 49

Dengue-Pipeline by Molplex Ltd., H1 2015 50

Dengue-Pipeline by Myelo Therapeutics GmbH, H1 2015 51

Dengue-Pipeline by NanoViricides, Inc., H1 2015 52

Dengue-Pipeline by Panacea Biotec Limited, H1 2015 53

Dengue-Pipeline by PaxVax, H1 2015 54

Dengue-Pipeline by Prosetta Antiviral Inc., H1 2015 55

Dengue-Pipeline by RFS Pharma, LLC, H1 2015 56

Dengue-Pipeline by Sanofi Pasteur SA, H1 2015 57

Dengue-Pipeline by Sarepta Therapeutics, Inc., H1 2015 58

Dengue-Pipeline by SIGA Technologies, Inc., H1 2015 59

Dengue-Pipeline by SKAU Vaccines ApS, H1 2015 60

Dengue-Pipeline by Takeda Pharmaceutical Company Limited, H1 2015 61

Dengue-Pipeline by TechnoVax, Inc., H1 2015 62

Dengue-Pipeline by Themis Bioscience GmbH, H1 2015 63

Dengue-Pipeline by United Therapeutics Corporation, H1 2015 64

Dengue-Pipeline by VaxInnate Corporation, H1 2015 65

Dengue-Pipeline by Visterra, Inc., H1 2015 66

Assessment by Monotherapy Products, H1 2015 67

Number of Products by Stage and Target, H1 2015 69

Number of Products by Stage and Mechanism of Action, H1 2015 71

Number of Products by Stage and Route of Administration, H1 2015 73

Number of Products by Stage and Molecule Type, H1 2015 75

Dengue Therapeutics-Recent Pipeline Updates, H1 2015 165

Dengue-Dormant Projects, H1 2015 171

Dengue-Discontinued Products, H1 2015 173

List of Figures

Number of Products under Development for Dengue, H1 2015 16

Number of Products under Development for Dengue-Comparative Analysis, H1 2015 17

Number of Products under Development by Companies, H1 2015 18

Number of Products under Investigation by Universities/Institutes, H1 2015 22

Comparative Analysis by Clinical Stage Development, H1 2015 25

Comparative Analysis by Early Stage Products, H1 2015 26

Assessment by Monotherapy Products, H1 2015 67

Number of Products by Stage and Top 10 Targets, H1 2015 68

Number of Products by Top 10 Mechanism of Actions, H1 2015 70

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 71

Number of Products by Top 10 Routes of Administration, H1 2015 72

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 73

Number of Products by Top 10 Molecule Types, H1 2015 74

Number of Products by Stage and Top 10 Molecule Types, H1 2015 75

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@]

Agilvax, Inc.

AltraVax Inc.

Arbovax, Inc.

BioDiem Ltd

Biotron Limited

Cocrystal Pharma, Inc.

Codagenix, Inc.

FIT Biotech Oyj

GlaxoSmithKline plc

Humabs BioMed SA

Immunovaccine, Inc.

Johnson & Johnson

Kineta, Inc.

MacroGenics, Inc.

Medivir AB

Merck & Co., Inc.

Molplex Ltd.

Myelo Therapeutics GmbH

NanoViricides, Inc.

Panacea Biotec Limited


Prosetta Antiviral Inc.

RFS Pharma, LLC

Sanofi Pasteur SA

Sarepta Therapeutics, Inc.

SIGA Technologies, Inc.

SKAU Vaccines ApS

Takeda Pharmaceutical Company Limited

TechnoVax, Inc.

Themis Bioscience GmbH

United Therapeutics Corporation

VaxInnate Corporation

Visterra, Inc.

Dengue Therapeutic Products under Development, Key Players in Dengue Therapeutics, Dengue Pipeline Overview, Dengue Pipeline, Dengue Pipeline Assessment

Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

query [@]